NewcelX Advances IND-Enabling Work Following Successful FDA Pre-IND Meeting
What happened
NewcelX Ltd., a regenerative medicine company, successfully concluded a Type B Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on September 28, 2026. The meeting provided constructive feedback and alignment on the proposed development strategy for its lead program, NCEL-101. Following this successful meeting, NewcelX has a clear path forward regarding the remaining IND-enabling work required for its planned Phase 1/2a clinical trial.
From manilatimes.net
Why it matters
The successful meeting clarified the regulatory pathway for NCEL-101's clinical development. This paves the way for NewcelX to advance its preclinical, manufacturing, and regulatory activities toward the planned human trials for Type 1 Diabetes.
From manilatimes.net
Who's involved
- FDAU.S. Food and Drug Administration reviewed the development strategy for the drug candidate.
Keep exploring
The entities involved
Related events
- FDA provided responses to a Type B meeting request and Oragenics conducted a Phase IIa trial in Australia.
- Cereno Scientific is seeking FDA review for its IND package while conducting a Phase I PK bridging study in Sweden.
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.